For Surgeons  

Thoragraft logo blue.png

manufacturer of...

Choice One.jpeg

Significantly improve your patient outcomes

ThoraGraft is designed with a thick, fibrous bone matrix that allows the graft to “SET” the fractured sternum and functions as a fusion device.  “Wolf’s Law” states that bone needs compression and must be held static over time to grow and heal.  ThoraGraft works with the wire construct to immobilize the sternal wound by allowing the edges of the sternal halves to imbed themselves into the graft.


Working with the tension of the wires, this holds the entire construct statis, which aids compression, thereby helping “Wolf’s Law” to take effect.


ThoraGraft is designed from fibrous human demineralized bone (“DBM”) tissue with a thickness of at least 4mm in width and a length of 100mm that runs the length of the sternum. 


The benefit of the thick, fibrous DBM bone matrix of ThoraGraft is that it gives the graft porous characteristics that allow blood and fluid to penetrate, wick into, pass through and become absorbed by the graft. This design encourages the sternal wound to begin clotting as the graft presses into the raw edges of the bone. This hemostasis benefit of the graft helps the incised bone stop bleeding more quickly than just wiring alone. In the first 80 cases performed, ThoraGraft consistently demonstrated this clotting advantage. The average decrease in post-operative blood drainage went from approximately 400ml to less than 70ml with use of the ThoraGraft.


In addition, by extubating the patient early, this led to a reduction in post-operative pneumonia. This risk is decreased because the patient has the ability to clear fluid buildup in their lungs, from being intubated, hours earlier than the traditional procedure allow.


Early extubating also results in early release from an ICU for the patient which significantly reduces the overall cost for the hospital.


Schedule online. It's easy, fast and secure.